Year in Review

Transcriptional signatures of COPII vesicle and Golgi targeting were identified as potential novel response biomarkers to vidutolimod, a first-in-class CpG-A TLR9 agonist, in combination anti–PD-L1-targeted therapy. Read More ›

Combining anti–PD-(L)-1 with chemotherapy for the treatment of patients with a high PD-L1 expression level did not improve survival compared with anti–PD-(L)-1 monotherapy. Read More ›

The 5-year extended follow-up of CheckMate 227 demonstrated that nivolumab plus ipilimumab continued to provide durable clinical benefit in previously untreated patients with metastatic NSCLC compared with chemotherapy regardless of PD-L1 expression level. Read More ›

Mutations in the ATM gene, the most mutated DNA damage and repair gene in cancer, were found to define distinct subsets of patients with NSCLC with unique genomic characteristics, clinicopathologic features, and sensitivity to chemoimmunotherapy. Read More ›

A noncoding single-nucleotide polymorphism in the CTLA-4 gene was found to be common among responders to anti–PD-1/PD-L1 therapies, which may enhance the clinical effect of PD-1 blockade. Read More ›

In real-world practice, the combination of immune checkpoint inhibitors with chemotherapy in patients with metastatic NSCLC may delay progression compared with immune checkpoint inhibitors alone but does not affect long-term outcomes. Read More ›

Treatment of patients with advanced PD-L1–high NSCLC with a combination of immune checkpoint inhibitors and chemotherapy resulted in comparable or better outcomes than immune checkpoint inhibitors alone; however, tolerability was a limiting factor for elderly patients. Read More ›

Neoadjuvant nivolumab plus platinum-doublet chemotherapy resulted in clinically meaningful improvement in event-free survival and pathologic complete response in patients with resectable NSCLC compared with chemotherapy alone. Read More ›

Neoadjuvant treatment of patients with resectable early-stage NSCLC with durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab, the anti-NKG2A monoclonal antibody monalizumab, or the anti-STAT3 antisense oligonucleotide danvatirsen resulted in improved efficacy compared with durvalumab alone. Read More ›

The combination of canakinumab and pembrolizumab plus chemotherapy did not statistically improve efficacy as first-line treatment in patients with advanced NSCLC. Read More ›

Page 4 of 9